Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium - Archive ouverte HAL Access content directly
Journal Articles European Journal of Cancer Year : 2021

Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium

Claudia Pasqualini
Jonathan Rubino
Lydie Cassard
Windy Rondof
  • Function : Author
Jean-Yves Scoazec
Antonin Marchais
  • Function : Author
Lisa Boselli
Jonathan Grivel
  • Function : Author
Isabelle Aerts
  • Function : Author
Estelle Thebaud
  • Function : Author
Véronique Minard-Colin
  • Function : Author
Gilles Vassal
Birgit Geoerger
Not file

Dates and versions

hal-03625350 , version 1 (30-03-2022)

Identifiers

Cite

Claudia Pasqualini, Jonathan Rubino, Caroline Brard, Lydie Cassard, Nicolas André, et al.. Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. European Journal of Cancer, 2021, 150, pp.53-62. ⟨10.1016/j.ejca.2021.03.032⟩. ⟨hal-03625350⟩
20 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More